Small Molecules to Improve Myelination in Alzheimer's Disease and APOE4 Carriers
This technology introduces small-molecule therapies designed to treat Alzheimer’s disease by targeting APOE4-driven cholesterol dysregulation in the brain. It operates by using compounds such as cyclodextrins to reverse cholesterol synthesis and transport defects in oligodendrocytes, thereby restoring axonal myelination. Unlike traditional amyloid- or tau-focused approaches, this technology directly addresses APOE4-related metabolic dysfunction in glial cells, a key contributor to Alzheimer’s pathology.
Researchers
-
apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells
United States of America | Granted | 12,285,440 -
apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells
Patent Cooperation Treaty | Published application
Technology
The technology creates a small-molecule therapeutic that counteracts the impaired myelination caused by the APOE4 gene. The treatment involves administering compounds orally or in sustained-release formulations that correct cholesterol imbalances in oligodendrocytes caused by the APOE4 alteration of cholesterol synthesis and transport. Cyclodextrins reverse APOE4-associated cholesterol phenotypes, enhancing axonal myelination in preclinical models. Additionally, the ACSL1 inhibitors restore purinergic signaling and lipid balance. The compounds can be delivered orally or in sustained-release formulations, offering flexibility for clinical applications.
Problem Addressed
Current Alzheimer’s therapies fail to effectively address the genetic risk stemming from APOE4, which is present in 50-65% of patients and strongly linked to cognitive decline. APOE4 disrupts cholesterol biosynthesis and transport in oligodendrocyte, leading to hypomyelination and reduced neuronal support. Prior efforts targeting cholesterol have produced inconsistent results because they do not correct APOE4’s cell-specific metabolic defects. This invention directly addresses that gap by restoring cholesterol balance in oligodendrocytes to prevent or reverse myelination deficits.
Advantages
- Directly addresses APOE4-mediated cholesterol phenotype defects.
- Enhances oligodendrocyte function and axonal insulation.
- Provides small-molecule therapeutic, compatible with oral or sustained-release dosing and existing drug delivery platforms.
- Potential use in Alzheimer’s disease, cerebral amyloid angiopathy, and other hypomyelination disorders.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.